{"entity":{"id":"nct06731153","kind":"trial","name":"JAK1 Inhibitor Ivarmacitinib Reversing Immunotherapy Resistance in TNBC","aka":[],"tldr":"A phase 2 trial of camrelizumab and eribulin in triple-negative breast cancer, run by Fudan University, not yet recruiting.","summary":"JAK1 Inhibitor Ivarmacitinib Reversing Immunotherapy Resistance in TNBC is a phase 2, randomised interventional study registered as NCT06731153 by Fudan University, with a registry enrolment figure of 40 participants, started 2024-12 and due to reach its primary completion in 2027-06. Interventions recorded: Ivarmacitinib; Camrelizumab (SHR-1210); Eribulin. Conditions listed: Triple Negative Breast Cancer (TNBC); Metastatic Breast Cancer. Triple-negative eligibility wording from the registry: \"Metastatic or locally advanced, histologically documented TNBC;\". Sites: China. No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT06731153","url":"https://clinicaltrials.gov/study/NCT06731153"}],"tags":["ctgov-ingest","tnbc-deep-dive"],"related":[],"cancers":["tnbc-metastatic"],"sections":[],"technologies":["checkpoint-inhibitor","cytotoxic-chemotherapy"],"targets":[],"drugs":["camrelizumab","eribulin"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06731153","phase":"2","setting":"A Randomized, Controlled, Open-label, Phase II Clinical Study Evaluating the JAK1 Inhibitor Ivarmacitinib to Reverse Immunotherapy Resistance in Triple-negative Breast Cancer","sponsor":"Fudan University","enrolled":40,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06731153/","neighbours":{"cancer":[{"id":"tnbc-metastatic","kind":"cancer","name":"Metastatic triple-negative breast cancer","route":"/cancers/tnbc-metastatic/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"drug":[{"id":"camrelizumab","kind":"drug","name":"Camrelizumab","route":"/drugs/camrelizumab/"},{"id":"eribulin","kind":"drug","name":"Eribulin","route":"/drugs/eribulin/"}],"term":[{"id":"tnbc-trials-open-today","kind":"term","name":"Triple-negative breast cancer trials open today (registry snapshot and UK sites)","route":"/terms/tnbc-trials-open-today/"}]}}